サイト内検索


登録済み会員ログイン




未登録の方はこちらから登録できます。
新規会員登録


ご利用案内

ご利用案内


連絡先

TEL.03-5812-5270
FAX.03-3831-0495
E-mail:info@spi-information.com


関連サイト・サービス

市場調査のご依頼、専門分野のイベント・フォーラムの開催などは シード・プランニングにて承っております。

シードプランニング

世界の医療・医薬品産業レポートのデータベースサービスは、sekairyo.comにてご利用いただけます。

sekairyo.com

医療従事者へのあらゆる形態の調査は、メドサークルにお任せ下さい。

メドサークル


セキュリティについて

当サイトのコンテンツ利用時に送信される機密情報は、Verisign認証の元暗号化されて送信されます。


Global Drug Discovery Outsourcing Market Forecast to 2028

世界の創薬アウトソーシング市場2028年までの予測

レポート概要

ケミストリーサービス、, バイオ分析サービス、リード最適化、スクリーニング

世界の創薬アウトソーシング市場は2018年に226億9,000万ドルに達したと推定され、ケミストリーサービスのセグメントが最大のシェアを占めています。この市場は予測期間の前半には11.7%のCAGRで拡大する見込みです。

このレポートがもたらすメリット

読み進めるにつれて将来このセクターに出現するビジネスチャンスをどのようにして掴むことかできるか、その方法が明らかになります。ここには114の表、グラフを掲載 ‐ これらは全て他のどこからも入手できないものです。この195ページのレポートは世界の創薬アウトソーシング市場について明確で詳細な見識を与えます。さらに、市場に影響を及ぼす主な推進要因と課題を示します。

レポート詳細

目次

1. Report Overview
1.1 Global Drug Discovery Outsourcing Market Overview
1.2 Market Definition & Scope
1.3 Overview of Findings
1.4 Structure of the Report
1.5 Why You Should Read This Report?
1.6 Key Questions Answered by This Analytical Report
1.7 How This Report Delivers
1.8 Who is This Report For?
1.9 Methodology
1.9.1 Primary Research
1.9.2 Secondary Research
1.9.3 Market Evaluation & Forecasting Methodology
1.10 Frequently Asked Questions (FAQ)
1.11 Associated Visiongain Reports
1.12 About Visiongain

2. An Introduction to Drug Discovery Outsourcing
2.1 What is Outsourcing?
2.2 What is Drug Discovery Outsourcing?
2.3 Why Outsource Drug Discovery?
2.4 A Common Drug Discovery Model Includes Pharmaceutical Organizations Collaborating with Academia
2.5 The Outsource Model for Drug Development Increases Innovation
2.6 Outsourced Processes in Drug Discovery
2.7 Challenges with Drug Discovery Outsourcing
2.8 Emerging Markets are a Popular Destination for CROs
2.9 Strategic Partnerships to Acquisitions
2.10 Recent Drug Development Outsourcing Agreements

3. Global Drug Discovery Outsourcing Market and Service Area Submarkets: Market Forecast to 2028
3.1 Drug Discovery Outsourcing: Global Market Overview
3.2 The Global Drug Discovery Outsourcing Market: Revenue Forecast to 2028
3.3 Global Drug Discovery Outsourcing Market by Service Type: Revenue Forecast to 2028
3.4 Global Drug Discovery Outsourcing Market by Region: Revenue Forecast to 2028

4. Global Drug Discovery Outsourcing Market by Service Type: Forecast to 228
4.1 The Global Drug Discovery Outsourcing Market by Service Type: Revenue Forecast to 2028
4.2 Chemistry Services
4.2.1 Libraries
4.2.2 Building Blocks
4.2.3 Compound Synthesis
4.2.4 Global Drug Discovery Outsourcing Market: Chemistry Services Revenue Forecast to 2028
4.3 Biology Services
4.3.1 Target Identification
4.3.2 Target Validation
4.3.3 Global Drug Discovery Outsourcing Market: Biology Services Revenue Forecast to 2028
4.4 Lead Optimisation
4.4.1 ADMET Screening: Prevents Late Stage Failure of Clinical Trials
4.4.2 Global Drug Discovery Outsourcing Market: Lead Optimisation Revenue Forecast to 2028
4.5 Lead Identification and Screening
4.5.1 Methods of Screening in Drug Discovery
4.5.2 Primary Screening
4.5.3 Global Drug Discovery Outsourcing Market: Lead Identification and Screening Revenue Forecast to 2028

5. Global Drug Discovery Outsourcing Market by Regional and National Market: Forecast to 2028
5.1 Drug Discovery Outsourcing Overview
5.2 The Leading National Markets in the Drug Discovery Outsourcing Market Forecast to 2028
5.3 North America
5.3.1 North America Drug Discovery Outsourcing Market by Service Type: Revenue Forecast to 2028
5.3.2 North America Drug Discovery Outsourcing Market by Country: Revenue Forecast to 2028
5.3.3 US Drug Discovery Outsourcing Market: Revenue Forecast to 2028
5.3.3.1 Canada Drug Discovery Outsourcing Market, Revenue Forecast to 2028
5.3.3.2 Mexico Drug Discovery Outsourcing Market: Revenue Forecast to 2028
5.4 Europe
5.4.1 Europe Drug Discovery Outsourcing Market by Service Type: Revenue Forecast to 2028
5.4.2 Europe Drug Discovery Outsourcing Market by Country: Revenue Forecast to 2028
5.4.2.1 Germany Drug Discovery Outsourcing Market: Revenue Forecast to 2028
5.4.2.2 France Drug Discovery Outsourcing Market: Revenue Forecast to 2028
5.4.2.3 United Kingdom Drug Discovery Outsourcing Market: Revenue Forecast to 2028
5.4.2.4 Italy Drug Discovery Outsourcing Market: Revenue Forecast to 2028
5.4.2.5 Spain Drug Discovery Outsourcing Market: Revenue Forecast to 2028
5.4.2.6 Russia Drug Discovery Outsourcing Market: Revenue Forecast, 2018-2028
5.5 Asia-Pacific
5.5.1 Asia-Pacific Drug Discovery Outsourcing Market by Service Type: Revenue Forecast to 2028
5.5.2 Asia-Pacific Drug Discovery Outsourcing Market by Country: Revenue Forecast to 2028
5.5.3 Japan Drug Discovery Outsourcing Market: Revenue Forecast to 2028
5.5.4 China Drug Discovery Outsourcing Market: Revenue Forecast to 2028
5.5.4.1 Challenges to China’s Growth
5.5.5 Australia Drug Discovery Outsourcing Market: Revenue Forecast to 2028
5.5.6 South Korea Drug Discovery Outsourcing Market: Revenue Forecast to 2028
5.5.7 India Drug Discovery Outsourcing Market: Revenue Forecast to 2028
5.6 LAMEA
5.6.1LAMEA Drug Discovery Outsourcing Market by Service Type: Revenue Forecast to 2028
5.6.2 LAMEA Drug Discovery Outsourcing Market by Country: Revenue Forecast to 2028
5.6.3 Brazil Drug Discovery Outsourcing Market: Revenue Forecast to 2028
5.6.4 Saudi Arabia Drug Discovery Outsourcing Market, Revenue Forecast to 2028
5.6.5 Republic of South Africa Drug Discovery Outsourcing Market: Revenue Forecast to 2028

6. Leading Companies in Drug Discovery Outsourcing Market
6.1 Drug Discovery Outsourcing: A Fragmented and Growing Marketplace
6.2 Characteristics of Leading Contract Research Organisations
6.2.1 A Highly Quality Workforce
6.2.2 Emphasis on Intellectual Property Protection
6.2.3 Long Term Working Relationship
6.2.4 Success in Project Completion
6.2.5 Internal Drug Discovery Programmes
6.3 Service Offerings of Leading Companies in the Drug Discovery Outsourcing Market
6.3.1 List of Key Participating Players in Drug Discovery Outsourcing Market
6.3.2 Albany Molecular Research (AMRI)
6.3.2.1 Company Overview
6.3.2.2 Historical Sales and Financial Performance, 2013-2016
6.3.2.3 AMRI’s Drug Discovery Services
6.3.2.4 Internal Portfolio of Drug Discovery and Development Programme Collaborations
6.3.3 Evotec AG
6.3.3.1 Evotec AG Financial Performance, 2013-2017
6.3.3.2 Evotec AG Sales Forecast, 2018-2028
6.3.3.3 Evotec AG Recent Strategic Moves & Development
6.3.3.3.1 Partnership with Boehringer Ingelheim Pharma
6.3.3.3.2 Collaboration with CHDI
6.3.3.3.3 Collaboration with MedImmune
6.3.3.3.4 Collaboration with UCB Pharma
6.3.3.3.5 Collaboration with Janssen
6.3.3.3.6 Partnership with Bayer Pharmaceuticals
6.3.3.3.7 Partnership with AstraZeneca
6.3.3.3.8 Partnership with Johnson & Johnson
6.3.3.3.9 Partnership with Sanofi
6.3.3.3.10 Extended Partnership with Evotec
6.3.3.3.11 Collaboration with TESARO, Inc.
6.3.3.3.12 Collaboration with Petra Pharma Corporation
6.3.3.3.13 Collaboration with Carna Biosciences, Incorporated
6.3.3.3.14 Collaboration with Celgene Corporation
6.3.3.3.15 Partnership with Sanofi
6.3.3.3.16 Collaboration with Bayer AG
6.3.3.3.17 Partnership with Novo Nordisk
6.3.3.3.18 Partnership with CENTOGENE AG
6.3.3.3.19 Collaboration with Almirall, S.A.
6.3.4 Aptuit
6.3.4.1 INDIGO: Accelerating Early Drug Candidates
6.3.4.2 Aptuit Clinical Trial Supplies
6.3.4.3 Strategic Partnerships, Acquisitions and Divestitures
6.3.4.3.1 Divestiture of Aseptic Clinical Manufacturing
6.3.4.3.2 Partnership with Siena Biotech
6.3.4.3.3 Aptuit’s Extended Partnership with GSK for Verona Centre
6.3.4.3.4 Partnership with Laurus Labs
6.3.4.3.5 Collaboration with Celgene Corporation
6.3.4.3.6 Partnership with Chronos Therapeutics
6.3.4.3.7 Partnership with Chiesi Farmaceutici
6.3.4.3.8 Collaboration with the Molecular Surgical Laboratory of Massachusetts General Hospital (MGH)
6.3.4.3.9 Partnership with SAMDI Tech, Inc.
6.3.4.3.10 Collaboration with Bioversys AG
6.3.4.3.11 Partnership with Regulus Therapeutics Inc.
6.3.5 Cyprotex
6.3.6 Charles River Laboratories
6.3.6.1 Historical Sales and Recent Financial Performance, 2013-2017
6.3.6.2 Strategies: Charles River Laboratories
6.3.6.2.1 Acquisition of Galapagos’ CRO Services Division (BioFocus and Argenta)
6.3.6.2.2 Acquisition of VivoPath
6.3.6.2.3 Acquisition of ChanTest
6.3.6.2.4 Partnership with The Milner Therapeutics Institute
6.3.6.2.5 Partnership with Chiesi Farmaceutici SpA
6.3.6.2.6 Partnership with Nimbus Therapeutics
6.3.6.2.7 Partnership with Microbiologics
6.3.6.2.8 Agreement with CAS
6.3.6.2.9 Partnership Extension with Eisai Co., Ltd.
6.3.6.2.10 Agreement with SenzaGen
6.3.6.2.11 Acquisition of Brains On-Line
6.3.6.2.12 Acquisition of KWS BioTest
6.3.6.2.13 Acquisition of MPI Research
6.3.6.2.14 Agreement with AstraZeneca
6.3.6.2.15 Partnership Extension with PathoQuest
6.3.6.3 Charles River Laboratories: Revenue and Financial Analysis, 2017
6.3.6.4 Charles River Laboratories Sales Forecast, 2018-2028
6.3.7 WIL Research Laboratories LLC
6.3.7.1 Focus on Preclinical Research
6.3.7.2 Acquisition of Midwest Bio Research
6.3.7.3 Acquisition of Ricerca Biosciences LLC
6.3.8 Covance (Acquired by Laboratory Corporation of America)
6.3.8.1 Covance: Historical Revenue and Financial Performance, 2010-2013
6.3.8.2 LabCorp Financial Performance, 2014-2017
6.3.8.3 Strategies: Covance
6.3.8.3.1 Agreement with Eli Lilly
6.3.8.3.2 Agreement with Kellogg Company
6.3.8.3.3 Early Stage Discovery Efforts
6.3.8.3.4 Agreement with Sanofi
6.3.8.3.5 Agreement with Bio Pontis Alliance
6.3.8.3.6 Agreement with Indiana Clinical and Translational Sciences Institute (CTSI)
6.3.8.3.7 Launch of Mobile Health Solutions
6.3.8.3.8 Business Expansion in the UK
6.3.8.3.9 Business Expansion in Precision Medicine
6.3.8.3.10 Acquisition of Chiltern
6.3.8.3.11 Introduced Dedicated Offering
6.3.8.3.12 Agreement with GlaxoSmithKline
6.3.8.3.13 Focused Unit on Biologic Drug Development
6.3.8.3.14 Acquisition of Sciformix Corporation
6.3.9 Domainex
6.3.9.1 Drug Pipeline
6.3.9.2 TBK1/ IKKε-Inhibitors
6.3.9.3 Methyltransferase (KMTS) Inhibitors
6.3.10 GenScript Biotech Corporation
6.3.10.1 GenScript: Revenue and Financial Analysis, 2017
6.3.10.2 GenScript: Agreements and Partnerships
6.3.11 Pharmaceutical Product Development (PPD)
6.3.11.1 PPD: Agreements, Strategic Partnerships and Private Merger
6.3.11.1.1 Partnership with GSK
6.3.11.1.2 Partnership with Elan
6.3.11.1.3 Acquisition of Acurian
6.3.11.1.4 Collaboration with Charité-Universitätsmedizin Berlin
6.3.11.1.5 Acquisition of RCT Logic’s Exclusive License
6.3.11.1.6 Partnership with ERT
6.3.11.1.7 Partnership with Shin Nippon Biomedical Laboratories Ltd.
6.3.11.1.8 Collaboration with HealthCore, Inc.
6.3.11.1.9 Collaboration with CISYS LifeSciences
6.3.11.1.10 Collaboration with Moderna Therapeutics
6.3.11.1.11 Acquisition of Evidera
6.3.11.1.12 Collaboration with Frenova Renal Research
6.3.11.1.13 Collaboration with Quotient Sciences
6.3.12 QuintilesIMS (IQVIA)
6.3.12.1 QuintilesIMS: Historical Revenue and Financial Performance, 2013-2017
6.3.12.2 QuintilesIMS: Strategic moves & developments
6.3.12.2.1 Development Deal with Merck
6.3.12.2.2 QuintilesIMS: Acquisition of Advion Bioanalytical Labs
6.3.12.2.3 QuintilesIMS: Shedding Jobs
6.3.12.2.4 Merger with IMS Health
6.3.12.3 QuintilesIMS Sales Forecast, 2017-2028
6.3.13 Selcia
6.3.13.1 A Strong Natural Product Chemistry Track Record
6.3.13.2 Selcia Product Portfolio
6.3.13.3 Selcia Strategic Moves
6.3.13.3.1 Collaboration with Cantab
6.3.13.3.2 Initiative with the University of Edinburgh
6.3.13.3.3 Collaboration with Janssen Pharmaceuticals Inc.
6.3.13.3.4 Collaboration with Gilead Sciences, Inc.
6.3.13.3.5 Collaboration with Parkinson’s UK
6.3.14 Viva Biotech (Shanghai) Ltd.
6.3.15 WuXi Apptec
6.3.15.1 WuxiTec Services & Solutions Offerings
6.3.15.2 WuXiAppTec: Historical Revenue and Financial Performance, 2010-2014
6.3.15.3 WuxiTec: Strategic Moves
6.3.15.3.1 Acquisition of Next CODE Health
6.3.15.3.2 Collaboration with Gilead Sciences, Inc.
6.3.15.3.3 Collaboration with Eli Lilly and Company
6.3.15.3.4 Acquisition of Crelux GmbH
6.3.15.3.5 Collaboration with Pelago Bioscience
6.3.15.3.6 Partnership with AutoGenomics
6.3.15.3.7 Acquisition of HD Biosciences
6.3.15.3.8 Acquisition of ResearchPoint Global
6.3.15.3.9 Partnership with Mayo Clinic
6.3.15.3.10 Collaboration with Regulus Therapeutics Inc.
6.3.15.3.11 Business Expansion in the U.S.
6.3.15.3.12 Partnership with Antengene Corporation

7. Qualitative Analysis of the Drug Discovery Outsourcing Market
7.1 Drivers and Restraints in the Drug Discovery Outsourcing Market
7.2 SWOT Analysis of the Drug Discovery Outsourcing Market, 2018-2028
7.2.1 Strengths
7.2.1.1 Cost Reduction: A Central Driver for Outsourcing
7.2.1.2 Accelerating the Discovery of Drug Candidates
7.2.1.3 Growth of Virtual Pharmaceutical Companies
7.2.1.4 Reduction in R&D capacity Within Big Pharma
7.2.2 Weaknesses
7.2.2.1 Slowing Trajectory of Growth for R&D Spending
7.2.2.2 Increasingly Saturated Market Requires Companies to Quickly Evolve
7.2.3 Opportunities
7.2.3.1 The Available Scope for the Expansion of CROs
7.2.3.2 Targeted Therapies: Advances in Biologics and Orphan Drugs
7.2.3.3 Increasing Development of Biologics and Biosimilars
7.2.4 Threats
7.2.4.1 A Competitive Market is Increasing Consolidation
7.2.4.2 Threat of Private Public Alliances
7.2.4.3 Intellectual Property Leaks
7.2.4.4 Challenges of Technology Transfer
7.3 Porter’s Five Forces Analysis of the Drug Discovery Outsourcing Market
7.3.1 Threat of New Entrants: Medium
7.3.2 Power of Suppliers: Medium
7.3.3 Threat of Substitutes: Medium
7.3.4 Power of Buyers: High
7.3.5 Rivalry Among Competitors: High

8. Conclusion
8.1 Market Overview
8.2 Lead Optimisation will be the Fastest Growing Sector
8.3 The Drug Discovery Outsourcing Market in Emerging Market Shows Huge Gains
8.4 Continued Growth in Alliances and Collaborations
8.5 Concluding Remarks

Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain report evaluation form

List of Tables
Table 2.1 Indication of Functions Outsourced in the Different Stages of the Drug R&D Process, 2017
Table 2.2 Selected Drug Discovery Outsourcing Alliances, 2013-2018
Table 3.1 PhMRA’s Historical Estimate for its Member’s Total R&D Spending ($bn), 1980-2016
Table 3.2 Global Drug Discovery Outsourcing Market Forecast: Revenue ($m), AGR (%), and CAGR (%) 2018-2028
Table 3.3 Global Drug Discovery Outsourcing Market by Service Type: Revenue ($mn), AGR (%) and CAGR (%) 2017-2028
Table 3.4 Global Drug Discovery Outsourcing Market by Leading Nationals: Revenue ($m), AGR (%) and CAGR (%), 2018-2028
Table 4.1 Global Drug Discovery Outsourcing Market: Revenue ($m), Revenue Share (%) by Service Type, 2017, 2023, 2028
Table 4.2 Global Drug Discovery Outsourcing Market: Chemistry Services Revenue ($m), AGR (%) and CAGR (%) 2018-2028
Table 4.3 Global Drug Discovery Outsourcing Market: Biology Services Revenue ($m), AGR (%) and CAGR (%) 2018-2028
Table 4.4 Global Drug Discovery Outsourcing Market: Lead Optimisation Revenue ($m), AGR (%) and CAGR (%) 2018-2028
Table 4.5: Selected Source for Lead Compounds
Table 4.6 Global Drug Discovery Outsourcing Market: Lead Identification and Screening Revenue ($m), AGR (%) and CAGR (%) 2018-2028
Table 5.1 Global Drug Discovery Outsourcing Market: Revenue ($m), Revenue Share (%) by Region, 2017, 2023, 2028
Table 5.2 North America Drug Discovery Outsourcing Market by Service Type: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
Table 5.3 North America Drug Discovery Outsourcing Market by Country: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
Table 5.4 US Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
Table 5.5: Canada Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
Table 5.6 Mexico Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
Table 5.7 Europe Drug Discovery Outsourcing Market by Service Type: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
Table 5.8 Europe Drug Discovery Outsourcing Market by Country: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
Table 5.9 Germany Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
Table 5.10 France Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
Table 5.11: United Kingdom Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 5.12: Italy Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
Table 5.13: Spain Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
Table 5.14: Russia Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.15: Asia-Pacific Drug Discovery Outsourcing Market by Service Type: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
Table 5.16: Asia-Pacific Drug Discovery Outsourcing Market by Country: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
Table 5.17: Japan Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
Table 5.18: China Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
Table 5.19: Australia Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
Table 5.20: South Korea Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
Table 5.21: India Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
Table 5.22: LAMEA Drug Discovery Outsourcing Market by Service Type: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
Table 5.23: LAMEA Drug Discovery Outsourcing Market by Country: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
Table 5.24: Brazil Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
Table 5.25: Saudi Arabia Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
Table 5.26: Republic of South Africa Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
Table 6.1: List of Key Participating Players
Table 6.2: Albany Molecular Research (AMRI): Historical Revenue ($m), 2013-2016
Table 6.3: AMRI: Service Offerings and Descriptions, 2017
Table 6.4: Evotec: Revenue and R&D Expenses ($m), 2013-2017
Table 6.5: Evotec AG Forecast: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 6.6: Selected Cyprotex Partnerships, 2015
Table 6.7: Charles River Laboratories: Historical Revenue ($m), 2013-2017
Table 6.8: Charles River Laboratories: Revenue ($m) by Segment, 2015-2017
Table 6.9: Charles River Laboratories: Revenue & %Change, 2015-2017
Table 6.10: Charles River Laboratories Forecast: Revenue ($m), AGR (%), CAGR (%), 2018-2028
Table 6.11: Covance: Historical Revenue ($bn), 2010-2013
Table 6.12: LabCorp: Historical Revenue ($m), 2014-2017
Table 6.13: Domainex Selected Collaborations
Table 6.14: Domainex: Drug Pipeline by Indication, 2018
Table 6.15: GenScript: Business Segments
Table 6.16: GenScript: Revenue by Business Segments ($m, %), 2016 & 2017
Table 6.17: QuintilesIMS: Revenue ($m) & AGR (%), 2013-2017
Table 6.18: QuintilesIMS Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2028
Table 6.19: Viva Biotech: Service Offerings
Table 6.20: WuXi AppTec: Historical Revenue ($m), By Business Segments, 2010-2014
Table 7.1 SWOT Analysis of the Drug Discovery Outsourcing Industry, 2017-2027
Table 8.1: The Global Drug Discovery Outsourcing Market Forecast: Revenue ($m), CAGR (%), 2017, 2023 & 2028
Table 8.2: Global Drug Discovery Outsourcing Market, Revenue ($m) by Service Type, 2017, 2023, 2028

List of Figures
Figure 2.1 Selected Tasks being Outsourced in the Pharma Industry, 2017
Figure 2.2 Stages of the Drug Development Cycle
Figure 3.1 PhMRA’s Historical Estimate for its Member’s Total R&D Spending ($bn), 2000-2016
Figure 3.2 Attrition Rate of Compounds at the Developmental Stages
Figure 3.3 Global Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
Figure 4.1 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Service Type, 2018
Figure 4.2 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Service Type, 2023
Figure 4.3 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Service Type, 2028
Figure 4.4 Global Drug Discovery Outsourcing Market Revenue ($m) by Service Type, 2018-2028
Figure 4.5 Global Drug Discovery Outsourcing Market: Chemistry Services Revenue ($m), AGR (%), 2018-2028
Figure 4.6 Global Drug Discovery Outsourcing Market: Biology Services Revenue ($m), AGR (%), 2018-2028
Figure 4.7: An Overview of ADMET Screening in Drug Discovery
Figure 4.8 Global Drug Discovery Outsourcing Market: Lead Optimisation Revenue ($m), AGR (%), 2017-2028
Figure 4.8 Typical Steps in the Lead Screening Process
Figure 4.9 Global Drug Discovery Outsourcing Market: Lead Identification and Screening Revenue ($m), AGR (%), 2018-2028
Figure 5.1 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Region, 2017
Figure 5.2 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Region, 2023
Figure 5.3. The Global Drug Discovery Outsourcing Market: Market Shares (%) by Region, 2028
Figure 5.4 Global Drug Discovery Outsourcing Market Revenue ($m) by Leading Nationals, 2018-2028
Figure 5.5 US Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
Figure 5.6: Canada Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
Figure 5.7 Mexico Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
Figure 5.8 Germany Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
Figure 5.9: France Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
Figure 5.10: United Kingdom Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
Figure 5.11: Italy Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
Figure 5.12: Spain Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
Figure 5.13: Russia Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
Figure 5.14: Japan Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2017-2028
Figure 5.15: China Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
Figure 5.16: Australia Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
Figure 5.17: South Korea Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
Figure 5.18: India Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
Figure 5.19: Brazil Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
Figure 5.20: Saudi Arabia Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
Figure 5.21: Republic of South Africa Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
Figure 6.1: Albany Molecular Research (AMRI): Historical Revenue ($m), 2013-2016
Figure 6.2: Evotec AG Forecast: Revenue ($m), AGR (%), 2017-2028
Figure 6.3: Charles River Laboratories: Historical Revenue ($m), 2013-2017
Figure 6.4: Charles River Laboratories: Revenue Share (%) by Segment, 2017
Figure 6.5: Charles River Laboratories: Revenue & %Change, 2015-2017
Figure 6.6: Charles River Laboratories Forecast: Revenue ($m), AGR (%), 2017-2028
Figure 6.7: Covance: Historical Revenue ($m), 2010-2013
Figure 6.8: Covance: Revenue Share (%) by Segment, 2013
Figure 6.9: LabCorp: Historical Revenue ($m), 2014-2017
Figure 6.10: LabCorp: Revenue Share (%) by Segment, 2017
Figure 6.11: GenScript: Revenue by Business Segments (%), 2017
Figure 6.12: QuintilesIMS: Revenue ($m), 2013-2017
Figure 6.13: QuintilesIMS Forecast: Revenue ($bn), AGR (%), 2017-2028
Figure 7.1: The Drug Discovery Outsourcing Market: Drivers and Restraints, 2018-2028
Figure 7.2: Porter’s Five Forces Analysis of the Companion Diagnostics Market, 2018-2028
Figure 8.1: The Global Drug Discovery Outsourcing Market Forecast: Revenue ($m), 2017, 2023, 2028
Figure 8.2: The Global Drug Discovery Outsourcing Market Forecast: Revenue ($m) by Service Type, 2017, 2023, 2028

発刊日

2019/04/16

体裁

PDF / 195ページ

販売価格

2,699GBP

発行

Visiongain

備考

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※販売価格はシングルユーザーライセンスのものとなります。
※シングルユーザーライセンスのレポートは印刷不可、およびライセンス期間は1年となります。
※印刷可能のレポートをご希望の場合は、デパートメントライセンス(ライセンス期間1年、ユーザー数5人)をご検討ください。
※詳しくはお問い合わせください。

関連カテゴリ

アウトソーシング

購入・お問い合わせ

このレポートを購入

詳細を問い合わせる


PAGE